HALO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HALO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Halozyme Therapeutics's cost of goods sold for the three months ended in Dec. 2023 was $52.3 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $192.4 Mil.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Halozyme Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was 77.27%.
Cost of Goods Sold is also directly linked to Inventory Turnover. Halozyme Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 was 0.41.
The historical data trend for Halozyme Therapeutics's Cost of Goods Sold can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cost of Goods Sold | Get a 7-Day Free Trial | 45.55 | 43.37 | 81.41 | 139.30 | 192.36 |
Halozyme Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cost of Goods Sold | Get a 7-Day Free Trial | 42.12 | 35.17 | 50.07 | 54.82 | 52.30 |
Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.
Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $192.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (NAS:HALO) Cost of Goods Sold Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Halozyme Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:
Gross Margin % | = | (Revenue | - | Cost of Goods Sold) | / | Revenue |
= | (230.039 | - | 52.298) | / | 230.039 | |
= | 77.27 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:
Halozyme Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 52.298 | / | 128.261 | |
= | 0.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Halozyme Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Labarre | officer: SVP, Chief Technical Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Helen Torley | director, officer: President and CEO | C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Jeffrey William Henderson | director | 7000 CARDINAL PLACE, DUBLIN OH 43017 |
Nicole Labrosse | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Matthew L. Posard | director | 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037 |
Akiko Moni Miyashita | director | 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501 |
Mark Howard Snyder | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
Jean-pierre Bizzari | director | 235 LAUREL LN, HAVERFOLD PA 19041 |
Kenneth J Kelley | director | 1331 HILLVIEW DRIVE, MENLO PARK CA 94025 |
Elaine D Sun | officer: SVP, Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Masaru Matsuda | officer: SVP, General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: SVP, Chief Commerical Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire PRNewswire • 04-25-2023
By PRNewswire • 11-14-2023
By PRNewswire • 01-18-2024
By PRNewswire • 07-17-2023
By PRNewswire • 01-12-2024
By PRNewswire • 11-27-2023
By PRNewswire • 08-31-2023
By PRNewswire • 10-16-2023
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire PRNewswire • 06-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.